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The selective impact of strategies for prevention of PD-related peritonitis (PDrP) may have
modified, in the long term, the causal spectrum, clinical presentation and outcomes of these
infections.
Objectives
To compare trends in the incidence of PDrP by different microorganisms during a 30-year
period, with a particular focus on streptococcal infections. To analyze the clinical presenta-
tion and outcomes of these infections. Secondarily, to investigate how the isolation of differ-
ent species of streptococci can influence the clinical course of PDrP by this genus of
bacteria.
Method
Following a retrospective, observational design we investigated 1061 PDrP (1990–2019).
We used joinpoint regression analysis to explore trends in the incidence of PDrP by different
microorganisms, and compared the risk profile (Cox), clinical presentation and outcomes
(logistic regression) of these infections.
Main results
Our data showed a progressive decline in the incidence of PDrP by staphylococci and Gram
negative bacteria, while the absolute rates of streptococcal (average annual percent change
+1.6%, 95% CI -0.1/+3.2) and polymicrobial (+1.8%, +0.1/+3.5) infections tended to
increase, during the same period. Remarkably, streptococci were isolated in 58.6% of poly-
microbial infections, and patients who suffered a streptococcal PDrP had a 35.8% chance of
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presenting at least one other infection by the same genus. The risk profile for streptococcal
infections was comparable to that observed for PDrP overall. Streptococcal PDrP were
associated with a severe initial inflammatory response, but their clinical course was gener-
ally nonaggressive thereafter. We did not observe a differential effect of different groups of
streptococci on the clinical presentation or outcome of PDrP.
Conclusions
Time trends in the incidence of PDrP by different microorganisms have granted streptococci
an increasing relevance as causative agents of these infections, during the last three
decades. This behaviour suggests that current measures of prevention of PDrP may not be
sufficiently effective, in the case of this genus of microorganisms.
Introduction
Peritonitis (PDrP) represents one of the most feared complications of chronic Peritoneal Dial-
ysis (PD), associating significant rates of mortality [1,2] and PD technique failure [3–6]. The
incidence of PDrP declined markedly between 1985 and 1995, after the introduction of Y-set,
double bag systems, but improvements have been slower thereafter [5,7], and rates as high as
one episode every two patient-years are still considered acceptable by current standards [8].
Singular advances, including the introduction of low glucose degradation products-based
(low-GDP) solutions, may have been beneficial, but their impact has been disappointing, in
clinical terms [9]. On the contrary, comprehensive approaches to prevention, including con-
tinuous quality improvement strategies, have provided a renewed hope of progress [10], and
may mark the route to an optimized control of these infections.
Staphylococci are still viewed as the main source of PD-related PDrP [1,11,12]. However, a
selective impact of preventive measures, preferentially oriented to reduce the consequences of
touch contamination and catheter-related infections, may have influenced the etiologic spectrum
and the strategies of management of PDrP [8], because these measures do not protect evenly from
infections by different microorganisms. In particular, streptococcal infections have been a subject
of limited attention in the past, due to the perceptions that these infections are relatively infre-
quent (with reported relative incidences of 5–12% of all PDrP) and follow a relatively benign clini-
cal course [13–16]. On the other hand, the taxonomy and nomenclature of the ubiquitous genus
Streptococcus has been reviewed in the last years [17] and, aside from single case reports, informa-
tion on the compared aggressiveness of PDrP by different members of this family of microorgan-
isms is scarce [18]. Finally, streptococci may be a common component of polymicrobial PDrP,
but the real incidence of this circumstance and its clinical significance are also unclear.
Following an observational, retrospective design, we have investigated time trends in the
incidence of PDrP in our centre during a period of 30 years. Our hypothesis was that advances
in the prevention and management of PDrP could have modified the etiologic and clinical




Following an observational, retrospective design, we analyzed trends in the incidence and out-
comes of PDrP diagnosed in our centre between January 1990 and December 2019. Our main
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focus was to disclose changes in the incidences of PDrP by different causative agents, with a
particular interest in streptococcal infections (primary objective). For this purpose, we catego-
rized the study follow-up into six periods (1990–94, 1995–99, 2000–04, 2005–09, 2010–14 and
2015–19). We also analyzed the clinical presentation, treatment and outcomes of the afore-
mentioned groups, with streptococcal infections again as the main reference. The main clinical
outcome was a composite of PDrP-related death, drop-out to hemodialysis for more than 3
months and need for catheter removal to control the infection (treatment failure). Secondarily,
we investigated the clinical significance of PDrP by different species of streptococci, as also the
role of these bacteria in polymicrobial infections (secondary objectives).
The study complied with the principles of the Declaration of Helsinki and the ethical
requirements of our centre for retrospective observational studies. The study protocol was
evaluated and approved by the local Ethical Committee of A Coruña-Ferrol Hospitals (code
2020/190). Oral informed consent was a requisite for inclusion of the minority of eligible indi-
viduals who were accessible at the time of initiation of the study, and conveniently registered
in the clinical records of the patients. In the case of patients not available for consent (due to
demise or loss to follow-up), inclusion was approved by the above mentioned Ethical
Committee.
Study population
We recruited for this study all patients starting PD in our unit between January 1, 1990 and
October 1, 2019. Follow-up was closed by December 31, 2019. We excluded from analysis
patients <18 years of age, those with a follow-up on PD<1 month, and those with inadequate
clinical records. No patient denied consent for participation.
Study variables and strategy of analysis
Our interest was addressed to episodes of PDrP occurring during the study period. In particu-
lar, we focused on streptococcal infections, and used PDrP of other causes as control groups.
For this purpose, we categorized the following study groups:
1. Streptococcus spp.
2. Staphylococcus aureus (SAu).
3. Coagulase-negative staphylococci (CNSt).
4. Enterobacteriaceae and nonfermenting Gram negative bacteria (GNB).
5. Polymicrobial PDrP, excluding those with a rampant intestinal origin (immediate surgical
approach or isolation of multiple enteric microorganismos, including intestinal anaerobics)
6. Culture-negative infections.
We did not consider PDrP with primary isolation of yeasts (n = 30), filamentous fungi
(n = 2) or mycobacteria (n = 5), due to their low frequency and particular significance. PDrP
caused by other less frequent (less than 50 cases) Gram positive [e.g. Enterococcus spp (n = 35)
or Corynebacterium spp (n = 13)] or Gram negative bacteria [e.g. Neisseria spp (n = 10)] were
also excluded from analysis. Only 4 episodes of PDrP by SAu (7.0%) were caused by methicil-
lin-resistnat strains, and this small subset was not further individualized for analysis.
The main study variable was the causative organism of each PDrP, always with a main
focus on streptococcal infections. We explored:
1. The time course of the incidence of PDrP by different causative microorganisms.
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2. The risk profile for different types of PDrP, according to the demographic and clinical char-
acteristics of the study population: age, gender, underlying kidney disease, diabetes mellitus,
previous episodes of PDrP, treatment with immunosuppressants, PD vintage, PD modality,
use of icodextrin, SAu carriage [19], comorbidity score (Charlson), malnutrition (subjective
global assessment), socioeconomic status, assisted versus autonomous PD, body mass index
(weight/height2), hemoglobin, albumin (autoanalyzer), C-reactive protein (Immunoturbi-
dimetry), glomerular filtration rate (GFR)(mean of urea and creatinine renal clearances),
and peritoneal transport (D/P ratio of creatinine at 240´ D/Pcrea).
3. Clinical presentation of the PDrP: simultaneous catheter-related infection (catheter-related
PDrP), hospitalization, peritoneal cell-count at baseline, and number of days until complete
clinical, bacteriologic and cytologic remission or catheter removal.
4. Initial and susceptibility-oriented antimicrobial therapy
5. Outcomes of PDrP:
• Peritoneal catheter removed
• Transfer to hemodialysis for at least 3 months after the infection
• Death for any reason during hospital admission or within 30 days after initiation of the
episode.
• Treatment failure, defined by any of the three previous outcomes (main clinical outcome).
PDrP was defined according to the ISPD guidelines [8,20]. The same sources were used for
definition of relapsing, recurrent and repeat PDrP. The initial diagnostic procedures (includ-
ing systematic sampling of dialysate for cytologic and microbiologic evaluation) have
remained essentially stable during the whole study period. Our protocol for initial treatment of
PDrP was based on intraperitoneal ciprofloxacin between 1990 and 2007. In September 2007,
we switched to intravenous vancomycin + intraperitoneal cefotaxime, after susceptibility of
CNSt to ciprofloxacin fell below acceptable standards. In our Unit, hospital admission for
PDrP is indicated for high-risk patients, infections with an aggressive clinical presentation,
treatment failure after oriented antimicrobial therapy and isolation of microorganisms
demanding in-centre management. Outpatient management includes a clinical check-up
every other day until full remission of infection, and then antibiotic therapy during 2–3 weeks,
according to the ISPD recommendations [8,20].
We used integrated Y systems for continuous ambulatory PD, and Home Choice (Baxter,
Deerfield, IL, USA) cyclers for automated PD. Conventional, lactate-based PD solutions were
used until March 2008, when patients were switched to low-GDP solutions. We have per-
formed systematic screening of nasal (since 1990) and pericatheter (since 1996) carriage of
SAu to patients and PD partners during the whole study period. Carriers were treated with
nasal and pericatheter mupirocin.
Statistics. Continuous variables are expressed as mean ± SD, or as median (interquartile
range), in case of markedly non-normal distribution. Categorical variables are presented as the
number of cases (%). Basic univariate comparisons were produced by means of usual paramet-
ric [two-tailed Student’s t test, ANOVA (Scheffé)] and nonparametric tests (χ2 distribution,
Mann Whitney, Spearman’s correlation coefficient), as needed.
We used joinpoint regression analysis to disclose time trends in the overall and by-causative
agent rates of incidence of PDrP, calculating the annual percent change (APC), and the aver-
age annual percent change (AAPC) for the whole study period [21]. The risk profile for PDrP
by different families of microorganisms (survival to the first episode) was first explored by
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means of Kaplan Meier plots (log rank test), and then by stepwise Cox models. For Kaplan
Meier analyses, we categorized numerical variables by tertiles. For multivariate analyses, we
considered only first order interaction terms. PD vintage (categorized in three periods: 1990–
99, 2000–09 and 2010–19) was systematically considered as a control variable in these multi-
variate models.
The clinical presentation and antimicrobial therapy characteristics are presented using a
descriptive approach, including univariate comparisons. The same applies for outcomes, in
which case we also carried out a multivariate approach (stepwise logistic regression), to catego-
rize better the role of different bacteria, on these outcomes. Risk estimations are presented as
Odds ratios (OR) (logistic regression) or hazard ratios (HRs)(Cox), with 95% confidence inter-
vals (CI). A two-tailed p-value <0.05 was considered significant (the software used for time
trends analyses does not provide exact p values).
We used the IBM-SPSS 19.0 software for general data management and statistic analyses.
Time trends analyses were produced with the help of the Joinpoint Regression Program
4.7.0.0. (Feb 2019; Statistical Research and Applications Branch, National Cancer Institute).
Results
Overview and time trends
The study population included 878 patients, after excluding 25 other individuals who did not
meet the inclusion criteria. Their main baseline characteristics are presented in Table 1. Of the
whole study group, 468 patients (52.6%) suffered at least one episode of PDrP, and 158
(18.0%) suffered at least one streptococcal PDrP. The latter was the etiologic group with the
highest incidence of repeat infection (35.8%). Thirty (19.0%) of these patients suffered two,
and 25 others (15.8%) more than two monobacterial streptococcal PDrP during follow-up
(range 3–7 episodes). Only CNSt approached this figure (29.1%, including 12.6% with more
than two episodes), which was markedly lower in the cases of SAu (11.6%), GNB (21.2%),
polymicrobial (11.1%) and culture-negative PDrP (16.0%)(p = 0.003). Median delays to the
first episode of PDrP were 8 (interquartile range 3 to 17) (overall) and 12 months (interquartile
range 5 to 24)(streptococcal PDrP).
Overall, we recorded 1061 episodes of PDrP during follow-up, caused by streptococci
(n = 235, 22.1%), SAu (n = 57, 5.4%), CNSt (n = 285, 26.9%) or GNB (n = 175, 16.5%). We also
registered 133 polymicrobial (12.5%) and 126 (11.9%) culture-negative infections. Regarding
streptococcal infections, 223 were caused by viridans group streptococci and only 12 by non-
viridans species. Among viridans streptococci, the mitis (including oralis, sanguis and gordo-
nii)(n = 92) and the salivarius (including vestibularis)(n = 85) groups predominated. On the
other hand, at least one streptococcal strain was isolated in 78 polymicrobial infections
(58.6%) (Table 2). Streptococci were less frequently identified in the latter group between 1990
and 1999 (38.9%), but kept consistently above 60% after 2000 (p = 0.016).
Table 3 displays the absolute and relative incidences of PDrP during the different study
periods. Joinpoint analyses disclosed a progressive decrease in the incidence of PDrP overall.
This tendence was supported by a declining incidence of infections by staphylococci and GNB
(Table 3, Fig 1), while an opposite trend was observed for polymicrobial and streptococcal
infections (not significant in the latter case) (Fig 1). Separate APC analyses showed rather
homogeneous time courses for these trends, except in the cases of PDrP overall [AAPC -5,4%
per year 1990–1999 (95% CI -9.0/-1.6, p<0,001) versus -0.7% per year 2000–2019 (95% CI
-1.7/+0.2)] and infections by Staphylococcus aureus [AAPC -12.4% per year 1990–1999 (95%
CI -22.0/-1.6), 17.5% per year2000-2008 (95% CI -1.9/+40.8) and -21.7% per year 2009–2019
(95% CI -31.3/-10.7)].
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Risk profile for PDrP
Kaplan Meier analysis disclosed correlations between the probability of presenting PDrP (any
cause) during follow-up, on one side, and older age (p = 0.023 log rank), higher Charlson’s
score (p = 0.008), lower GFR (p = 0.035), higher C-reactive protein levels (p = 0.012), higher
body mass index (p = 0.035), and family-assisted PD (p = 0.045), on the other. Patients on
automated PD also exhibited a trend to a lower risk of infection than those on CAPD






Enterobacteriaceae and nonfermenting Gram negative bacteria 83
Other 8
https://doi.org/10.1371/journal.pone.0244283.t002
Table 1. Baseline characteristics of the study population.
Age (years) 59.2 (15.6)




Vascular (including nephroangiosclerosis) 84 (9.6)
Cystic 76 (8.7)
Systemic diseases (including paraproteinemias) 46 (5.2)
Diabetic nephropathy 264 (30.0)
Other/Unknown 194 (22.1)
Diabetes (%) 310 (39.4)
Charlson’s score 4,1 (2.0)
Recent/Ongoing immunosuppression (%) 85 (9.7)
Malnutrition (%) 83 (9.4)
Body mass index (Kg/m2) 26,0 (4.9)
Low socioeconomic status (%) 281 (32.0)
Family-assisted PD (%) 347 (39.6)




Modality of PD (Automated PD/CAPD)(%) 274/604 (31.2/68.8)
Icodextrin (%) 184 (21.0)
D/P creatinine 240’, baseline PET (n = 664) 67,9 (12.1)
Staphylococcus aureus carrier (%) 383 (43.6)
Glomerular filtration rate (mL/minute) 6,2 (4.1)
Hemoglobin (g/dL) 10,5 (1.6)
Plasma albumin (g/L) 37,1 (5.6)
Serum C reactive protein (mg/dL)(n = 717) 0.59 (0.28–1.45)
Follow-up (months) 28.9 (25.7)
Figures denote mean values ± standard deviation, median with interquartile range (numerical variables) or absolute
numbers (%) (categorical variables)
Keys: PD: Peritoneal Dialysis; CAPD: Continuous Ambulatory Peritoneal Dialysis; PET: Peritoneal equilibration test
https://doi.org/10.1371/journal.pone.0244283.t001
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(p = 0.07). On the other hand, the risk of suffering streptococcal PDrP was univariately linked
to older age (p = 0.003), lower plasma albumin (p = 0.041), higher body mass index
(p = 0.021), lower blood haemoglobin (p = 0.047) and automated PD rather than CAPD
(p = 0.050). PD vintage was a univariate predictor of the risk of streptococcal (p = 0.004), but
not overall PDrP (p = 0.124)(other variables displayed in Table 1 not significant).
Table 4 shows the multivariate (Cox) risk profile for PDrP overall, and streptococcal PDrP.
Both models were quite similar, except for a clearly stronger impact of PD vintage on the risk
of streptococcal infection, and a more marked association of baseline GFR with the later risk
of PDrP overall.
Clinical presentation according to causative microorganism
The main clinical characteristics of PDrP by different causative microorganisms are displayed
in Table 5. We did not record a single instance of streptococcal catheter-related PDrP between
1990 and 2019.
Streptococcal PDrP associated the most severe initial inflammatory reaction of all the study
groups, as estimated from the baseline peritoneal cell count and the proportion of polymor-
phonuclear leukocytes. Otherwise, the clinical presentation of streptococcal PDrP showed sim-
ilarities to infections by CNSt and culture-negative PDrP. Final antimicrobial therapy of these
infections was based on intraperitoneal ciprofloxacin (until 2007), cephalosporins and vanco-
mycin; only 15.0% of cases were finally treated with an antibiotic association.
Table 3. Time course of the absolute and relative rates of incidence of PD-related peritonitis of different etiologies.
90–94 95–99 00–04 05–09 10–14 15–19
Follow-up (months) 3558 4748 5495 4823 4182 4442
Follow-up (patient-years) 296.5 395.7 457.9 401.9 348.5 370.2
ABSOLUTE RATES (episodes/patient/year)
All infections (n) 190 188 200 183 154 146
Incidence 0.64 0.48 0.44 0.45 0.44 0.39
Streptococcus spp (n) 31 25 50 36 48 45
Incidence 0.104 0.063 0.109 0.089 0.138 0.122
Staphylococcus aureus (n) 13 10 7 21 4 2
Incidence 0.043 0.025 0.015 0.052 0.001 0.005
Coagulase negative Staphylococcus spp (n) 69 59 59 51 26 21
Incidence 0.233 0.149 0.129 0.127 0.074 0.057
Gram negative bacteria� (n) 29 35 32 32 26 21
Incidence 0.098 0.088 0.070 0.079 0.074 0.057
Polymicrobial (n) 11 25 24 17 26 30
Incidence 0.037 0.063 0.052 0.042 0.074 0.081
Negative culture (n) 14 23 24 19 22 24
Incidence 0.047 0.058 0.052 0.047 0.063 0.065
RELATIVE RATES (% of all episodes of PDrP)
Streptococcus spp 16.3 13.3 25.2 19.7 31.2 31.0
Staphylococcus aureus 6.8 5.3 3.5 11.5 2.6 1.4
Coagulase negative Staphylococcus spp 36.3 31.6 29.7 28.0 16.9 14.5
Gram negative bacteria� 15.3 18.7 16.0 17.5 16.9 14.5
Polymicrobial 5.8 13.3 12.0 9.3 16.9 20.7
Culture-negative 7.4 12.3 12.0 10.4 14.3 16.6
� Enterobacteriaceae + Nonfermenting Gram negative bacteria
https://doi.org/10.1371/journal.pone.0244283.t003
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Clinical outcomes
The main clinical outcomes of PDrP are presented in Table 6. Remarkably, streptococcal PDrP
carried the highest probability of uneventful continuation of PD. Catheter removal was less
frequent than in any other type of PDrP, except culture-negative PDrP (p = 0.04 versus CNSt).
The risk of relapse, in opposition to the case of repeat infection (see above) was low, and treat-
ment failure was less frequent than in any other group, although the difference with CNSt
(p = 0.072) and negative-culture PDrP (p = 0.11) did not reach statistical significance.
Table 7 presents the results of multivariate analysis for the main outcomes. Streptococcal
PDrP carried a better prognosis than infections by SAu or GNB, and similar to CNSt and cul-
ture-negative infections.
Fig 1. Relative incidence of peritoneal infection by different causative microorganisms during six consecutive
5-year periods (upper), and Average Annual Percent Changes (AAPC) in the absolute rates of incidence during
the 30-year study period.
https://doi.org/10.1371/journal.pone.0244283.g001
Table 4. Risk profile for peritoneal infection (overall) and streptococcal peritonitis. Multivariate analysis.
Overall Streptococcal
HR 95% CI P value HR 95% CI P value
PD vintage (ref. 1990–99)
2000–09 1.21 0.94–1.57 0.11 1.71 1.22–2.62 0.009
2010–19 0.97 0.72–1.32 0.94 1.77 1.12–2.80 0.015
Age (per year) 1.01 1.00–1.03 0.026 1.02 1.01–1.04 0.001
Plasma albumin (per g/L) 0.98 0.96–0.99 0.021 0.96 0.93–0.99 0.011
GFR (per mL/min) 0.97 0.94–0.99 0.029 - - -
Body mass index (per Kg/m2) 1.03 1.00–1.05 0.021 1.04 1.00–1.07 0.046
Stepwise Cox’s regression. First-order interaction terms not significant. For the overall risk of PDrP, -2log likelihood 4429.30, χ2 28.93, p<0.0005. For streptococcal
PDrP, -2log likelihood 1692.86, χ2 36.52, p<0.0005
Keys: HR: Hazard Ratio; CI: Confidence interval; PD: Peritoneal Dialysis; GFR: Glomerular Filtration Rate
https://doi.org/10.1371/journal.pone.0244283.t004
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Table 5. Clinical presentation and antimicrobial therapy.
Strept. SAu CNS GNB Poly Culture-negative P value
Catheter-related (%) 0 34.1 2.3 14.2 0.8 0 0.0005
Hospitalization (%) 14.0 40.4 13.3 33.0 26.7 143 0.0005
Number of in-hospital days for admitted patients 10.7 (9.4) 16.3 (16.2) 13.3 (10.2) 20.5 (165) 12.9 (10.4) 13.8 (13.1) 0.045
Initial peritoneal cell count (per mm3) 5431 (6995) 2483 (2379) 2650 (5276) 3466 (5463) 3240 (3004) 2151 (3431) 0.0005
Initial neutrophil count (%) 78.9 (12.3) 74.5 (12.7) 72.1 (15.4) 77.3 (14.0) 79.6 (14.9) 68.8 (18.3) 0.0005
Initial treatment (%) 0.0005
Ciprofloxacin 55.6 59.3 75.5 69.5 44.9 59.1
Vanco + Cephalosporin 42.7 35.2 21.1 26.5 53.5 37.6
Other/No data 1.7 5.5 3.4 4.0 1.6 3.3
Final treatment (%) 0.0005
Ciprofloxacin 19.8 16.6 36.1 33.7 3.3 40.3
Cephalosporin 28.3 5.6 4.7 23.3 164 6.0
Carbapenem 1.4 1.9 0 8.4 4.9 2.7
Vancomycin 33.8 18.5 36.0 0 6.6 4.7
Antibiotic association� 15.0 55.6 22.4 28.9 66.9 44.3
Other/No data 1.7 1.8 0.8 5.7 1.9 2.0
Number of days of antibiotic therapy 15.6 (4.8) 22.1 (8.0) 15.8 (5.9) 16.6 (6.1) 19.7 (5.2) 12.9 (5.1) 0.0005
� Most common antibiotic associations Vancomycin + Cephalosporin/Rifampicin (Gram positive microorganisms) or Cephalosporin + Aminoglycoside (Gram
negative microorganisms)
Figures denote % of cases (categorical variables) or mean (standard deviation)(numerical variables). Comparison by χ2 distribution and one-way ANOVA. P values
denote overall significance. In bold, categories presenting a significant difference with streptococcal infections (Scheffé)
Keys: Strept: Streptococci; SAU: Staphylococcus aureus; CNS: Coagulase-negative staphylococci; GNB: Gram negative bacteria (Enterobacteriaceae + Nonfermenting
Gram negative bacteria); Poly: Polymicrobial
https://doi.org/10.1371/journal.pone.0244283.t005
Table 6. Clinical outcomes.
Strept. SAu CNS GNB Poly Culture-negative P value
Time to remission or catheter removal (days) 5.7 (3.9) 5.3 (3.6) 5.2 (3.5) 5.1 (4.7) 4.3 (2.2) 5.0 (2.9) 0.033
Catheter removed (%) 3.0 31.6 7.0 23.1 8.1 2.3 0.0005
Relapse (%) 10.7 8.8 17.9 19.8 9.5 7.6 0.003
Recurrence (%) 0.16
Other bacteria 0.4 0 2.1 4.4 0.7 1.8
Yeasts 2.6 3.5 2.5 2.2 2.2 0.8
Main outcomes (%) 0.0005
PD continued >3 months 97.0 76.9 96.1 85.2 91.9 94.0
Drop-out to Hemodialysis 0 8.8 2.8 6.6 2.2 0.8
PDrP-related death 3.0 12.3 1.1 8.2 5.9 5.3
Treatment failure (%) 4.7 42.1 8.4 26.9 11.1 7.5 0.0005
Figures denote % of cases (categorical variables) or mean (standard deviation)(numerical variables). Comparison by χ2 distribution and one-way ANOVA. P values
denote overall significance. In bold, categories presenting a significant difference with streptococcal infections (Scheffé)
Keys: Strept: Streptococci; SAU: Staphylococcus aureus; CNS: Coagulase-negative staphylococci; GNB: Gram negative bacteria (Enterobacteriaceae + Nonfermenting
Gram negative bacteria); Poly: Polymicrobial
https://doi.org/10.1371/journal.pone.0244283.t006
PLOS ONE Streptococcal peritoneal infections in PD
PLOS ONE | https://doi.org/10.1371/journal.pone.0244283 December 21, 2020 9 / 15
Comparisons of PDrP by different species of streptococci
We compared the clinical presentation and outcomes of four different subgroups of strepto-
cocci, namely mitis/oralis/sanguis/gordoni (n = 92), salivarius/vestibularis (n = 85), other viri-
dans (n = 46) and non-viridans (n = 12). We were unable to disclose any significant
differences or trends, regarding the variables displayed in Tables 5 and 6 (data not presented).
Table 7. Predictors of clinical outcomes. Multivariate analysis.
OR 95% CI P value
CATHETER REMOVAL
Age (per year) 0.97 0.96–0.99 0.002
Time on PD at the time of infection (per month) 1.02 1.01–1.03 0.0005
PD vintage (Ref. 1990–99) 0.86
2000–2009 1.06 0.84–1.76
2010–2019 0.78 0.36–1.43
Causative agent of infection (Ref. Streptococcus spp)
Staphylococcus aureus 10.85 4.09–18.82 0.0005
Coagulase-negative Staphylococcus spp 1.73 0.70–4.28 0.23
Gram negative bacteria 8.39 3.62–19.48 0.0005
Polymicrobial 2.19 0.81–5.92 0.12
Culture-negative 0.72 0.18–2.85 0.64
PERITONEAL INFECTION-RELATED DEATH
Age (per year) 1.10 1.06–1.14 0.0005
Time on PD at the time of infection (per month) 1.03 1.02–1.04 0.0005
Charlson’s score (per point) 1.15 1.03–1.33 0.019
Recent/Active immunosuppression 4.99 1.91–13.02 0.001
PD vintage (Ref. 1990–99) 0.80
2000–2009 1.53 0.70–3.36
2010–2019 0.64 0.26–1.56
Causative agent of infection (Ref. Streptococcus spp)
Staphylococcus aureus 10.50 3.05–36.12 0.0005
Coagulase-negative Staphylococcus spp 0.25 0.06–1.02 0.054
Gram negative bacteria 2.74 1.03–7.30 0.041
Polymicrobial 1.66 0.55–5.03 0.36
Culture-negative 2.02 0.65–6.29 0.22
TREATMENT FAILURE
Time on PD at the time of infection (per month) 1.02 1.01–1.03 0.0005
PD vintage (Ref. 1990–99) 0.45
2000–2009 1.22 0.78–1.92
2010–2019 0.89 0.52–1.52
Causative agent of infection (Ref. Streptococcus spp)
Staphylococcus aureus 14,30 6.28–32.59 0.0005
Coagulase-negative Staphylococcus spp 1.41 0.66–3.00 0.38
Gram negative bacteria 6.90 3.41–13.90 0.0005
Polymicrobial 2.00 0.88–4.58 0.09
Culture-negative 1.76 0.98–2.31 0.22
Best models. Stepwise logistic regression analysis
Keys: OR: Odds ratio; CI: Confidence interval; PD: Peritoneal Dialysis; Treatment failure: At least one of: catheter removal, death or drop-out to hemodialysis for at least
3 months
https://doi.org/10.1371/journal.pone.0244283.t007
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Clinical significance of the isolation of streptococci in polymicrobial PDrP
As previously stated, at least one streptococcal strain was isolated in 78 of the 133 polymicro-
bial PDrP included in the analysis. In 28 cases, polymicrobial PDrP was caused by 2 different
strains of streptococci. Polymicrobial PDrP with presence of streptococci presented with mar-
ginally higher peritoneal cell counts (3501 vs 2764 cells/mm3, p = 0.092) and % of neutrophils
(81.9 vs 75.9%, p = 0.031), than infections without participation of these bacteria. We did not
detect any other clinical difference, between these subsets (data not presented).
Discussion
Our results provide clues to understand how the causative spectrum of PDrP may have evolved,
during the last three decades. The systematic implementation of measures of prevention, essen-
tially oriented to reduce touch contamination and catheter-related PDrP [8,22] resulted in a
progressive decline of the incidence of infections by staphylococci and GNB (Table 3, Fig 1). On
the contrary, in a setting of slowly decreasing incidence of PDrP, we observed trends to an
increase in the rates of streptococcal and polymicrobial infections, with the particularity that a
majority of the latter included isolation of streptococci. Overall, streptococci were isolated in
41.3% of the PDrP diagnosed between 2010 and 2019. Thinking in positive terms, this change
may have been beneficial, because streptococcal PDrP associated better outcomes than infec-
tions by SAu or GNB (and similar to CNst) (Tables 6 and 7). From an opposite point of view,
this evolution suggests that current prevention measures may not be effective, to reduce the risk
of streptococcal infections. This finding should not be completely unexpected. First, catheter-
related streptococcal PDrP is an infrequent event (Table 5) [23,24], downplaying the capacity of
catheter care to prevent this complication. Touch contamination is a potential source of strepto-
coccal infection, but the ubiquity (skin, mouth, upper respiratory tract, upper and lower gastro-
intestinal tract) of this genus of bacteria [17] entails more potential foci of contamination and,
probably, a higher capacity for hematogenous spread than CNSt. The circumstance that 35.8%
of the patients who presented streptococcal PDrP suffered at least one other episode of infection
by the same genus suggests a persistence and/or multiplicity of foci of infection. Other studies
have detected a significant incidence of repeat streptococcal PDrP, although not to the extent
observed in our study [14,15]. The oral cavity is a subject of particular concern as a source of
streptococcal PDrP, due to a high degree of colonization by this family of bacteria [25] and to a
potential for both hematogenous spread and direct contamination, particularly if face masks are
used inappropriately during the PD exchange [8]. On the other hand, the high proportion of
polymicrobial PDrP with isolation of streptococci [13,14,16] suggests that the lower gastrointes-
tinal tract may be another significant source of infections by these bacteria. Unfortunately, we
were unable to create a specific risk profile for streptococcal PDrP (Table 4), partly due to the
nonavailability of potentially relevant variables, including bucodental care, adherence to the use
of face masks during the PD changes or intestinal disorders. Older age, hypoalbuminemia and
overweight was associated with a higher risk of streptococcal PDrP, but this predictive model
lacked specificity, because these factors were also linked to the general risk of PDrP [26–28].
This inability to establish a specific predictive model for streptococcal PDrP was also observed
in the best powered study so far [14].
Our results disclosed a higher relative incidence of streptococci in both monobacterial and
polymicrobial PDrP than previous reports [11–14,16,29–32]. However, most of the cited studies
investigated patients started on PD in the 1990s’, when the incidence of streptococcal PDrP was
also lower in our centre. In addition, local factors, including differences concerning PD prac-
tices and the global incidence of PDrP, could help to explain this discrepancy. For instance,
irregular adherence to measures with a demonstrated efficacy to prevent staphylococcal PDrP
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[33] may associate a lower incidence of streptococcal infections [14,34,35]. The latter factor
could also explain why only some studies [12,13,36] were able to detect the trend to an increase
in the incidence of streptococcal PDrP, so clearly disclosed by our analysis. The exclusion by
protocol of rampant enteric PDrP and the high proportion of polymicrobial peritonitis with iso-
lation of streptococci may help to explain why, in our study, the observed outcomes of these
infections were more benign than usually reported (Table 6) [29,31].
The present study agrees, for the most part, with previous reports on the clinical presenta-
tion and outcome of streptococcal PDrP (Tables 5 and 6). These infections have a relatively
severe initial presentation, with a marked inflammatory response, as shown by the baseline
peritoneal cell counts (Table 5), and a relatively slow resolution (Table 6) [13]. However, initial
aggressiveness is usually followed by complete recovery with antibiotic therapy alone, with low
rates of hospital admission, catheter removal, relapse, recurrence and, most importantly, hard
outcomes (mortality, technique failure) (Table 7) [13–16,18]. Previous studies have shown that
the time course of peritoneal cellularity, rather than the initial count, is the best marker of out-
come of PDrP [37,38]. Our data also confirm that these bacteria are usually susceptible to com-
mon antibiotic regimes [39], as either vancomycin, betalactams or fluoroquinolones were able
to control streptococcal PDrP (Table 5) [14,15]. Current ISPD recommendations endorse the
use of ampicillin, for this purpose [8] but, in our unit, the success of the antimicrobials used
for initial management of PDrP explains why ampicillin was not a usual choice.
Our results do not suggest particularities for any subgroup of streptococci, regarding clinical
presentation or outcomes. Isolation of Streptococcus bovis has been linked to an increased risk
of colorectal cancer. We recorded 5 instances of this infection, and all followed an uneventful
clinical course, in agreement with a recent report [18]. We neither observed any significant
diference among polymicrobial PDrP with or without isolation of streptococci. Previous studies
have underlined that the isolation of GNB [31], intestinal anaerobics and Enterococcus faecium
[40] may represent better markers of a complicated outcome of polymicrobial PDrP.
Our study suffers significant limitations, including a retrospective, single-centre design, which
may overrate the effect of local factors. Some variables with a potential impact on the risk of strep-
tococcal PDrP (e.g. oropharingeal disorders) could not be recorded. Therapy used for treatment
of streptococcal infections may have been broader than necessary. On the other side, significant
strengths include the large time span, very appropriate to investigate time trends, and the high
quality of our database, which permitted a complete analysis of the study population.
In summary, the last decades have contemplated an increasing relevance of streptococci in
the causal spectrum of PDrP. This circumstance has been favoured by the concurrence of non-
significant trends to an increase in the incidence of infections by this family of microorgan-
isms, on one side, and simultaneous declines in the incidences of PDrP by staphylococci and
GNB, on the other. This time course suggests that current measures for prevention of PDrP
may not be sufficiently effective, for this genus of microorganisms. The facts that streptococcal
PDrP associate a high risk of repeat infections and that streptococci are frequently isolated in
polymicrobial infections reinforce this perception. Streptococcal PDrP are characterized by an
initially aggressive clinical course and a relatively slow resolution, but also by a usually
uneventful outcome with antibiotics alone. Future research will be necessary to improve pre-
vention of infections by this genus of Gram positive bacteria.
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